Liver Diseases  >>  Xifaxan (rifaximin)  >>  Phase 4
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health
NCT01842113: Quality of Life and Nutritional Improvements in Cirrhotic Patients

Terminated
4
4
US
Rifaximin, Xifaxan, Lactulose, Enulose, Generlac, Cholac, Constulose, Kristalose, Laxilose, Portalac, Hepatalac, Constilac, Lactulose Placebo, Rifaximin Placebo, Sugar Pill
Tampa General Hospital
Liver Cirrhosis, Hepatic Encephalopathy, Portal Hypertension
05/14
 
NCT01654939: Impact of an Antibiotic (Rifaximin) on Liver Scarring in HIV-Infected Patients With Liver Disease

Withdrawn
4
0
US
Rifaximin, XIFAXAN
Douglas T. Dieterich, Bausch Health Americas, Inc.
HIV, Hepatitis C
09/14
09/15
NCT01769040 / 2012-002890-71: Intestinal Decontamination With Rifaximin. The Inflammatory and Circulatory State in Patients With Cirrhosis

Completed
4
54
Europe
Rifaximin, Xifaxan, placebo
Copenhagen University Hospital, Hvidovre, Norgine, Region MidtJylland Denmark, Statens Serum Institut
Liver Cirrhosis, Ascites
01/16
01/16
RIFSYS, NCT02019784 / 2013-004708-20: Randomised Controlled Trial of Mechanistic Effects of Rifaximin in Cirrhosis and Chronic Hepatic Encephalopathy

Completed
4
38
Europe
Rifaximin-α, Targaxan (brand name), Placebo Oral Tablet
King's College Hospital NHS Trust, King's College London
Liver Cirrhosis, Hepatoencephalopathy, Early Fatal Progressive
06/16
10/16

Download Options